Abaloparatide

Status:
Do Not Prescribe (DNP)
Decision Date:
June 2023
 

Comments

DNP: Treatment of osteoporosis in postmenopausal women at increased risk of fracture. Awaiting national guidance. 

ICB commissioned 

search again